•   
  •   
  •   

US Covid-19 treatment: Remdesivir does not fully convince

15:23  23 may  2020
15:23  23 may  2020 Source:   latribune.fr

SC patients with COVID-19 get Remdesivir for treatment

  SC patients with COVID-19 get Remdesivir for treatment SC patients with COVID-19 get Remdesivir for treatmentThe pharmaceutical company that owns the drug, Gilead Sciences, donated doses of Remdesivir to the federal government.

Remdesivir , an antiviral drug designed to treat both hepatitis and a common respiratory virus, seemed fated to join thousands of other failed medications But on Friday, the Food and Drug Administration issued an emergency approval for remdesivir as a treatment for patients severely ill with Covid - 19

Remdesivir (RDV) is a synthetic molecule in the antiviral class of medications. It is under investigation for treatment of the COVID - 19 coronavirus pandemic Does remdesivir (RDV) appear to be effective against COVID - 19 , based on the limited evidence available? Is remdesivir FDA approved for treating

Le Remdesivir a également semblé réduire la mortalité : 7,1% des patients du groupe Remdesivir sont morts sous 14 jours, contre 11,9% dans le groupe placebo, mais ce résultat est juste en-dessous du seuil de fiabilité statistique, et on ne peut exclure que la différence soit due au hasard. © Supplied by La Tribune Remdesivir also seemed to reduce mortality: 7.1% of patients in the Remdesivir group died within 14 days, compared with 11.9% in the placebo group, but this result is just below the statistical reliability threshold, and we cannot exclude that the difference is due to chance.

More than three weeks after a senior US scientist announced that an experimental drug called Remdesivir was speeding up the recovery of hospitalized Covid-19 patients, the study detailing the results was published Friday evening in a listed medical journal . Anthony Fauci, director of the Institute of Allergies and Infectious Diseases (NIAID), which conducted the clinical trial on a thousand patients in 10 countries, said on April 29, in the Oval Office of the White House, that preliminary data showed "that Remdesivir (had) a clear, significant and positive effect in reducing recovery time".

Large Study Finds No Benefit — and Potential Harm — in Using Hydroxychloroquine for COVID-19

  Large Study Finds No Benefit — and Potential Harm — in Using Hydroxychloroquine for COVID-19 It’s not the first study to find that hydroxychloroquine may not help COVID-19 patientsIn a study published May 22 in the journal Lancet, scientists in the U.S. and Switzerland report on an analysis of more than 96,000 people hospitalized with confirmed COVID-19 in 671 hospitals on six continents. Nearly 15,000 patients were treated with one of the following: chloroquine (which is an older version of hydroxychloroquine), hydroxychloroquine, or either of those drugs in combination with an antibiotic. The remainder did not receive any of these medications and served as the control.

Remdesivir is the antiviral drug for coronavirus that was originally developed to treat Ebola. The FDA action specifies the drug may be used for both adults and children with suspected or confirmed COVID - 19 diagnoses who are severely ill with low blood oxygen levels or who may be on a ventilator.

The experimental coronavirus treatment remdesivir has shortened the recovery time for COVID - 19 patients, according to data Remdesivir : what to know about potential coronavirus treatment . “It is a very important proof of concept because what it is proving is that a drug can

After review by a reading committee, the New England Journal of Medicine published the article detailing the results confirming the announcement made at the White House, which had caused a glimmer of hope in the world, in the absence of other effective therapy for the new coronavirus.

Decrease in mortality but ...

Remdesivir, injected daily intravenously for 10 days, accelerated the recovery of hospitalized patients of Covid-19, compared to a placebo: 11 days against 15 in median duration. Patients who were able to return home were considered to have recovered. The effect was greatest in hospitalized patients who were not on an artificial respirator. The authors conclude that it is best to start treatment with Remdesivir before the disease progresses to the point of requiring an artificial respirator. The antiviral, once developed in vain for Ebola, has also caused fewer side effects than placebo.

Global COVID-19 cases reach 5 million

  Global COVID-19 cases reach 5 million Here are the latest coronavirus updates from around the world.By Thursday night that number had passed 5.1 million, according to the university.

COVID - 19 is an emerging, rapidly evolving situation. Get the latest public health information from The study can be adapted to evaluate additional investigative treatments and to enroll participants at Although remdesivir has been administered to some patients with COVID - 19 , we do not have solid

Covid - 19 patients who are getting an experimental drug called remdesivir have been recovering quickly, with most However, the trial does not include what's known as a control group, so it will "We understand the urgent need for a COVID - 19 treatment and the resulting interest in data on our

Remdesivir also appeared to reduce mortality: 7.1% of patients in the Remdesivir group died within 14 days, compared with 11.9% in the placebo group, but this result is just below the statistical reliability threshold, and it cannot be excluded that the difference is due to chance. In all cases, Remdesivir therefore does not give a guarantee of survival, insist the authors of the trial. "It is clear that antiviral treatment will probably not be enough on its own," they write.

Combinations of treatments

The key to treatment of Covid-19 will undoubtedly lie in combinations of treatments, Remdesivir with other antivirals or other types of therapy. The laboratory that developed Remdesivir, Gilead, said Friday that results from its own clinical trials will be published soon. One of them shows that a treatment of five days, instead of 10 days, would be as effective, according to Merdad Parsey, medical director of Gilead Sciences.

In the United States, the Medicines Agency (FDA) authorized the emergency use of Remdesivir in hospitals on May 1, followed by Japan, while Europe is considering a similar decision.

Rwanda has enlisted anti-epidemic robots in its fight against coronavirus .
Rwanda has introduced robots as part of its fight against coronavirus. © Rwanda Biomedical Centre New robots have been donated to Rwanda's Ministry of Health to help fight the spread of coronavirus in the country With 314 confirmed cases of the virus as of May 22, the East African country has enlisted the help of five anti-epidemic robots to battle the virus. require(["medianetNativeAdOnArticle"], function (medianetNativeAdOnArticle) { medianetNativeAdOnArticle.

—   Share news in the SOC. Networks
usr: 7
This is interesting!